about
Aberrant Topological Patterns of Structural Cortical Networks in Psychogenic Erectile Dysfunction.Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidenceSafety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.Avanafil for male erectile dysfunction: a systematic review and meta-analysis.Aberrant Insula-Centered Functional Connectivity in Psychogenic Erectile Dysfunction Patients: A Resting-State fMRI Study.Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study.Future prospects in the treatment of erectile dysfunction: focus on avanafil.Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.Macrostructural alterations of subcortical grey matter in psychogenic erectile dysfunction.Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?Current Diagnosis and Management of Erectile DysfunctionA meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction.Analysis of prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors from the urology department and other departmentsComparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate CancerSildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.Ex vivo relaxation effect of Cuscuta chinensis extract on rabbit corpus cavernosum.Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.The use of phosphodiesterase 5 inhibitors with concomitant medications.Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectivesToward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunctionAn Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study.Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know.Stopwatch-assessed duration of erection: a new measure of the efficacy of erectile dysfunction treatments.Erectile dysfunction after radical prostatectomy: treatment options.Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Exercise therapy for sexual dysfunction after prostate cancer.Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.Effect of levitra on sustenance of erection (EROS): an open-label, prospective, multicenter, single-arm study to investigate erection duration measured by stopwatch with flexible dose vardenafil administered for 8 weeks in subjects with erectile dysComparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndromeThe Old Made New: Natural Compounds against Erectile Dysfunction.Inflatable penile prosthesis (IPP): diagnosis of complications.Routine cardiac assessment is not necessary for all patients with erectile dysfunction.Avanafil for the treatment of erectile dysfunction.
P2860
Q27316960-11E49586-ED86-4079-BEDD-BE0599D36BE1Q30739538-CD8AD033-03F7-4331-B4A8-501C7405E45AQ33289952-5EC5220F-BDCF-42CC-B69F-7CC500D33571Q33571010-AE2B87CA-6D9F-4504-A132-582C5A303779Q33606588-3DBD48B1-3BCC-4F7D-BDCF-28A8FBB894E0Q33621456-82DB978F-681D-488F-917F-EF1154ECA2CFQ33692697-B36C8573-5EF7-4ADC-89CC-F8698AEDFB50Q33880138-38103C47-AB8A-433C-B671-05E407635A69Q34029414-8633D8A0-D710-41B4-92DF-80BD1BD0F2BEQ34139231-1302199A-CD58-402C-AF8E-166E27E284A7Q34314201-2A405394-761F-4F99-9651-582640E0EA35Q34624315-674F5786-81B1-4447-B850-D03C23187934Q35050805-FA2404C5-3F5D-4E46-B72A-5BF50C74253CQ35384480-8DC7B3E8-EA5E-4912-B980-4998D176B9D4Q35628328-D46609F7-6321-4C2C-A78C-59EF3D5DA589Q35667309-3CF82F36-4619-4F16-97C4-1CE8AAB35651Q36127788-EBE5CA61-BD3C-465F-AF80-5F627427C83DQ37018954-48C22D5A-5A09-478F-8F66-4D8AC321B720Q37084163-D4AE27ED-996A-409D-9A54-A9AF25CA4D94Q37180996-31E92509-14E5-4A46-B5CA-E42C16034F9FQ37321940-66246BE1-9567-430E-B64A-D5BEE5F5AACBQ37423713-D006E4AA-E8C8-495A-A648-4F275BBBF7B6Q37427312-4B5B0C40-3127-4438-8DB0-C0ABF3724F4AQ37636060-1B6F1163-334D-488A-B84B-A01147BD3976Q37686844-19646170-8AA6-4356-ACD1-C13560FB8C20Q37810422-E29161AD-C237-4959-AFD0-C1F8F2D0C0C9Q37823211-A3A02B67-E38C-4F14-B230-CC3691CDC064Q37856241-2BDB6CB8-D233-4A25-99D0-962C28E10CF8Q37886052-ED8073F2-0288-4735-978B-CE7425DFB923Q38107001-A8432E0C-8740-4AE1-8791-0063D8F2E347Q38150112-51223D68-04D6-41E6-9562-31F5601F01D7Q38248275-F0FF309D-442D-418D-80D2-30DCA140C9D5Q38431092-944F19E3-46B2-4845-90EF-1EE3ADB854B3Q38436646-8850151F-5DDF-4067-A515-BCC6ACA61A3DQ38464139-53FFC23E-5166-4434-A496-B81FCCAA6C4AQ38472418-FC35EA2B-A8F3-4CA1-8878-81290CF07568Q38479677-4BC848D5-0F97-4491-B29A-1D5A0886F294Q38747338-5D6013CB-C71C-4525-BF66-7687B6E26DFCQ38832052-69FD0D6B-E941-4B0B-8F89-490D564CB2FDQ38896836-C47CBDB1-11C6-4C85-AB91-B8ABE5A52FA5
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
EAU Guidelines on erectile dysfunction: an update.
@ast
EAU Guidelines on erectile dysfunction: an update.
@en
type
label
EAU Guidelines on erectile dysfunction: an update.
@ast
EAU Guidelines on erectile dysfunction: an update.
@en
prefLabel
EAU Guidelines on erectile dysfunction: an update.
@ast
EAU Guidelines on erectile dysfunction: an update.
@en
P2093
P1433
P1476
EAU Guidelines on erectile dysfunction: an update.
@en
P2093
Dimitrios Hatzichristou
Edouard Amar
Eric Wespes
John Pryor
Kosta Hatzimouratidis
Yoram Vardi
P304
P356
10.1016/J.EURURO.2006.01.028
P407
P577
2006-02-09T00:00:00Z